Therachon
Webb1 juli 2024 · Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon … Webb17 aug. 2024 · Swiss-based biotech company, Therachon, which focuses on developing rare genetic disease treatments, says it has closed a $60 million round of funding as the company moves closer to a drug trial. The funding will be used to develop the company’s treatment for achondroplasia, the most common form of short limbed dwarfism, and …
Therachon
Did you know?
http://theracion.com/ Webbtherachon.com
Webb2 juli 2024 · Pfizer has announced it has completed its acquisition of US-based Therachon, a clinical stage biotechnology company focusing on rare diseases; the acquisition was first initiated in early May 2024.. According to the terms of the transaction, the Swiss pharma giant has bought Therachon for $340m with a potential $470m additional payments … WebbTherachon General Information. Description. Developer of novel therapeutics intended to facilitate treatment for rare genetic diseases. The company develops pipeline of therapeutics focused on rare gastrointestinal and musculoskeletal disorders and conditions, enabling medical practitioners to treat patients with short bowel syndrome …
Webb26 mars 2024 · We gave two presentations on investigational apraglutide for the treatment of #ShortBowelSyndrome at #ASPEN19!1. Complete Ph 1 trial results 2. Data from head-to-head rat studies comparing apraglutide to other GLP-2 analogs. http://therachon.com/research/
Webb5 sep. 2024 · Therachon Holding AG has developed products for the treatment of achondroplasia and short bowel syndrome.These include product candidate TA-46 for the treatment of achondroplasia, “a genetic condition and the most common form of short-limbed dwarfism”, as was reported in a press release from Pfizer.The U.S. …
WebbTherachon is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions … high chair designWebb8 maj 2024 · May 8, 2024. Pfizer has agreed to acquire Therachon Holdings for up to $810 million, the companies said today, in a deal intended to expand the buyer’s rare disease portfolio with a pipeline to ... high chair decorating first birthdayWebb31 jan. 2024 · The investigational drug, one of an early generation drummed up by the buzzy AI tools in biotech, works by inhibiting multiple tropomyosin-related kinases, which … high chair decorations diyWebb1 juli 2024 · Early clinical development program for achondroplasia augments Pfizer’s Rare Disease portfolio ... April 13, 2024 how far is sunderland to newcastleWebbTherAchon is a biotech company specializing in research and development. It is engaged in the development of a recombinant protein therapy for achondroplasia, the most … how far is suny oswego from meWebb8 maj 2024 · Under the terms of the agreement, Pfizer will acquire Therachon for $340 million upfront with an additional $470 million in additional payments contingent on the achievement of key milestones in the development and commercialization of TA-46 for the treatment of achondroplasia, a genetic condition and the most common form of short … how far is suny new paltz from meWebb29 aug. 2024 · About Therachon. Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. how far is sunrise fl from fort lauderdale fl